Pharmafile Logo
Pharmafocus logo
Advanced Search

Johnson & Johnson

Showing 15 posts of 147 posts found.

johnsonsss

Johnson & Johnson commits $2bn to new manufacturing facility in North Carolina, US

August 22, 2025
Manufacturing and Production Corporate, Fujifilm, Johnson & Johnson

Johnson & Johnson has announced a $2bn investment in a new manufacturing facility in Holly Springs, North Carolina, US, expanding …

News
Brain image

Johnson & Johnson submits FDA application for Caplyta to prevent schizophrenia relapse

July 18, 2025
Medical Communications, Research and Development CAPLYTA, Johnson & Johnson, Neurology, US Food and Drug Administration, neuroscience, new drug application, schizophrenia

Johnson & Johnson has submitted a supplemental New Drug Application to the US Food and Drug Administration (FDA) for Caplyta …

News

Johnson & Johnson seeks EMA approval to accelerate prostate cancer treatment

July 4, 2025
Medical Communications, Research and Development European Medicines Agency, Genito-Urinary system, Johnson & Johnson, Oncology, clinical trial, prostate cancer

Johnson & Johnson has submitted an application to the European Medicines Agency for an indication extension of Akeega (niraparib and …

News
money-2180330_960_720

Nanoform receives €5m loan from Finnish government to accelerate its nanotechnology

June 20, 2025
Freelancers, Licensing & business development, Research and Development Devices, Johnson & Johnson, Nanoform Finland, Oncology, amorphous solid dispersion technology, government loan, nanoparticle medicine, nanotechnology, prostate cancer

Nanoform Finland [Nanoform], a leading nanoparticle medicine company, is pleased to announce that Business Finland has approved a €5m research …

News

Johnson & Johnson presents promising data on leukaemia treatment

June 16, 2025
Medical Communications, Research and Development European Hematology Association, Janssen-Cilag, Johnson & Johnson, Oncology, chronic lymphocytic leukaemia, clinical trial

Janssen-Cilag, a Johnson & Johnson company, has announced results from a matching-adjusted indirect comparison presented at this year’s European Hematology …

News
bowel_cancer_screening

European Commission approves Johnson & Johnson’s Crohn’s disease therapy

May 12, 2025
Market Access, Research and Development, Sales and Marketing Crohn’s disease, European Commission, Gastrointestinal tract, Johnson & Johnson, guselkumab, marketing authorisation

The European Commission (EC) has granted Marketing Authorisation (MA) to Johnson & Johnson’s Tremfya (guselkumab) for the treatment of moderately …

News

Majority of Europeans trust technology to improve healthcare, Johnson & Johnson survey finds

May 8, 2025
Research and Development AI, Corporate, Devices, EU Data Act, HCPs, Johnson & Johnson, Pharmacy, digital technology, survey

A global survey by Johnson & Johnson MedTech has revealed that a majority of Europeans are willing to share their …

News
blood_test

Johnson & Johnson announces successful results from trial for myeloma treatment

April 16, 2025
Research and Development Johnson & Johnson, Oncology, myeloma, pharma, trial

Global healthcare company, Johnson & Johnson, announced that analysis of its Darzalex (daratumumab) therapy showed significantly longer progression-free survival (PFS) …

News

J&J seeks FDA approval of Spravato as monotherapy for treatment-resistant depression

July 24, 2024
Medical Communications J&J, Johnson & Johnson, Neurology, Spravato, treatment-resistant depression

Johnson & Johnson (J&J) has announced that it has submitted a supplemental New Drug Application (sNDA) to the US Food …

News

J&J’s Tremfya meets primary and secondary endpoints in UC maintenance study

May 21, 2024
Medical Communications Gastrointestinal tract, J&J, Johnson & Johnson, clinical trial, ulcerative colitis

Johnson & Johnson (J&J) has announced the first data from its phase 3 QUASAR maintenance study which assessed Tremfya (guselkumab) …

News

Johnson & Johnson to acquire Shockwave Medical

April 8, 2024
Business Services Cardiology, Johnson & Johnson, Shockwave Medical, acquisition

Johnson & Johnson (J&J) and Shockwave Medical have announced that they have entered into a definitive agreement under which J&J …

News

FDA approves J&J’s Opsynvi for PAH treatment

March 25, 2024
Medical Communications Cardiology, FDA, J&J, Johnson & Johnson, Opsynvi, pulmonary arterial hypertension

Johnson & Johnson (J&J) has announced that the US Food and Drug Administration (FDA) has approved Opsynvi (macitentan and tadalafil) …

News

Johnson & Johnson acquires Ambrx Biopharma for approximately $2bn

March 11, 2024
Business Services ADCs, Ambrx Biopharma, J&J, Johnson & Johnson, Oncology, acquisition

Johnson & Johnson (J&J) has announced that it has successfully completed its acquisition of Ambrx Biopharma in an all-cash merger …

News

FDA approves J&J’s Rybrevant with chemotherapy for NSCLC treatment

March 4, 2024
Medical Communications FDA, Johnson & Johnson, NSCLC, Oncology, Rybrevant

Johnson & Johnson have announced that the US Food and Drug Administration (FDA) has approved Rybrevant (amibantamab-vmjw) following a priority …

News

FDA approves Balversa for bladder cancer treatment

January 22, 2024
Medical Communications Balversa, FDA, Johnson & Johnson, Oncology, bladder cancer

Johnson & Johnson (J&J) have announced that the US Food and Drug Administration (FDA) has approved a supplemental New Drug …

News
The Gateway to Local Adoption Series

Latest content

STADA and Bio-Thera’s Gotenfia receives positive CHMP opinion for autoimmune diseases

December 18, 2025

Norgine enters exclusive licensing agreement with Vir Biotechnology

December 18, 2025

Incyclix appoints Kimberly Blackwell to Board of Directors

December 17, 2025

Hansa Biopharma appoints Max Sakajja as Vice President, General Manager Europe and International

December 17, 2025

GSK’s Exdensur receives MHRA approval for asthma and rhinosinusitis

December 16, 2025